AEterna Zentaris Inc. (AEZS)

[chmcnfunds]

New Investor Fact Sheet on the company website (link in iBox). Corporate Presentation remains outdated.

From the Fact Sheet:

"LEAD VALUE DRIVERS

Zoptarelin Doxorubicin
? Novel molecule composed of a targeted synthetic peptide carrier linked to doxorubicin
? Ongoing ZoptEC Phase 3 trial in advanced endometrial cancer under a Special Protocol Assessment
? 1rst interim analysis expected in H1 2015
? Potential additional indications (ex. ovarian, prostate, breast cancer therapies)
EstroGel®
? Non-patch transdermal estrogen therapy product commercialized by ASCEND Therapeutics in the U.S.
? Co-promotion agreement with ASCEND in the U.S.
? Promotion by Aeterna Zentaris sales force in the U.S. on a sales commissions basis"

AEZS